These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11350276)

  • 1. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
    Ahrén B
    Acta Physiol Scand; 2001 Feb; 171(2):161-7. PubMed ID: 11350276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents.
    Dhalla AK; Wong MY; Voshol PJ; Belardinelli L; Reaven GM
    Am J Physiol Endocrinol Metab; 2007 May; 292(5):E1358-63. PubMed ID: 17227958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal and dietary fat content-dependent islet adaptation to high-fat feeding-induced glucose intolerance in mice.
    Winzell MS; Magnusson C; Ahrén B
    Metabolism; 2007 Jan; 56(1):122-8. PubMed ID: 17161234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
    Santomauro AT; Boden G; Silva ME; Rocha DM; Santos RF; Ursich MJ; Strassmann PG; Wajchenberg BL
    Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet.
    Parlevliet ET; Heijboer AC; Schröder-van der Elst JP; Havekes LM; Romijn JA; Pijl H; Corssmit EP
    Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E142-7. PubMed ID: 17971509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
    Park KS; Kim CH; Lee MK; Shin CS; Park DJ; Kim SY; Cho BY; Lee HK
    Metabolism; 1999 Oct; 48(10):1318-21. PubMed ID: 10535397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production.
    Carey PE; Gerrard J; Cline GW; Dalla Man C; English PT; Firbank MJ; Cobelli C; Taylor R
    Am J Physiol Endocrinol Metab; 2005 Dec; 289(6):E941-7. PubMed ID: 15998660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin converting enzyme inhibition lowers body weight and improves glucose tolerance in C57BL/6J mice maintained on a high fat diet.
    Weisinger RS; Stanley TK; Begg DP; Weisinger HS; Spark KJ; Jois M
    Physiol Behav; 2009 Aug; 98(1-2):192-7. PubMed ID: 19465040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation.
    Vestergaard ET; Cichosz SL; Møller N; Jørgensen JOL; Fleischer J
    Br J Clin Pharmacol; 2017 Dec; 83(12):2671-2677. PubMed ID: 28736944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
    Alvarez P; Isidro L; Peinó R; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2003 Oct; 59(4):431-6. PubMed ID: 14510904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
    Blachère JC; Pérusse F; Bukowiecki LJ
    Metabolism; 2001 Aug; 50(8):945-51. PubMed ID: 11474483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
    Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
    Paolisso G; Tagliamonte MR; Rizzo MR; Gualdiero P; Saccomanno F; Gambardella A; Giugliano D; D'Onofrio F; Howard BV
    Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.
    Vestergaard ET; Hjelholt AJ; Kuhre RE; Møller N; Larraufie P; Gribble FM; Reimann F; Jessen N; Holst JJ; Jørgensen JOL
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2581-2592. PubMed ID: 30726969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
    Reimer MK; Holst JJ; Ahrén B
    Eur J Endocrinol; 2002 May; 146(5):717-27. PubMed ID: 11980629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
    Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
    Bajaj M; Suraamornkul S; Kashyap S; Cusi K; Mandarino L; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.